SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Duke Kahanamoku

PatientDuke Kahanamoku
Date of birth1959-08-24
IdentifiersMRN HR-ML050-SYN; SSN (made up) 000-50-6847
Document date2026-03-30
AuthorKawika Lindgren-Morrison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review: echocardiogram, heart failure consultation and the diagnosis. [S]

History of Present Illness

Mr. Kahanamoku returns two weeks after intake and is seen the same day by Dr. Abernathy-Chen of heart failure cardiology after his echocardiogram this morning. At his wish, two members of his ʻohana joined the discussion with the cardiologist. On furosemide 40 mg he has lost 2.6 kg; his ankles swell less, and he now sleeps on one pillow. He is still breathless walking up a slope and has not been back in the water. He has had no chest pain, palpitations, fainting or lightheadedness. He took his last lisinopril dose this morning. The echocardiogram shows a weak heart muscle with an ejection fraction of 30% and an old scar at the front and tip of the heart. [S]

ElementDetail
Since intakeWeight down 2.6 kg; less ankle swelling; one pillow
FunctionBreathless walking uphill; NYHA class III
EchocardiogramEjection fraction 30%; thinned, akinetic anterior wall and apex; moderate functional mitral regurgitation
Last lisinopril doseThis morning

Review of Systems

SystemResultFinding
CardiovascularPositiveBreathless walking uphill; less ankle swelling; no chest pain, palpitations or fainting
RespiratoryNegativeNo cough; orthopnea resolved
GenitourinaryNegativePassing more urine in the mornings
MusculoskeletalNegativeNo cramps

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-16completedS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Metoprolol tartrate 25 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2021-06-21 to 2026-03-30completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-30completedS
Furosemide 40 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-03-16 to 2026-04-27completedS
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinoprilOne tablet twice dailyOral route2026-03-30 to 2026-09-28completedS
Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrateOne tablet twice daily with foodOral route2026-03-30 to 2026-04-13completedS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route2026-03-30activeS
Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apartTwo infusions two weeks apartIntravenous route2026-03-30 to 2026-04-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-30Body height185cmS
2026-03-30Body weight95kgS
2026-03-30Body mass index (BMI) [Ratio]27.8kg/m2S
2026-03-30Systolic blood pressure134mm[Hg]S
2026-03-30Diastolic blood pressure82mm[Hg]S
2026-03-30Heart rate86/minS
2026-03-30Respiratory rate18/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-30Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-03-30Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
2026-03-30Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
2026-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M76mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-30Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
2026-03-30Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.6-2.6 mg/dLNormalS
2026-03-30Left ventricular Ejection fraction30%50-70%LowS

Physical Exam

Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]

SystemFinding
GeneralComfortable at rest; blood pressure 134/82, pulse 86; weight 95.0 kg, down 2.6 kg
NeckJugular venous pressure 3 cm above the sternal angle, down from 6
CardiovascularRegular rhythm; displaced apex; soft S3; apical systolic murmur
RespiratoryFine crackles at both bases only
ExtremitiesTrace ankle edema, from 2+

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction.
Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952activeconfirmed I25.2S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history.
Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime.
Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%)activeconfirmed E61.1S — Synthetic finding at the heart failure workup.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and heart rate (seated and standing)Every visitCompleted today134/82 mmHg, pulse 86
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today95.0 kg (down 2.6); jugular venous pressure 3 cm; basal crackles; trace edema; NYHA III
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six monthsCompleted todayTwo weeks after furosemide: sodium 137, potassium 3.9, creatinine 1.08 mg/dL (eGFR 76), magnesium 1.9
ImagingEchocardiogramAt diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained changeCompleted todayEjection fraction 30%; thinned, akinetic anterior wall and apex; left ventricular end-diastolic diameter 62 mm; moderate functional mitral regurgitation
ExaminationECG (rhythm and QRS width)At diagnosis and with change or device considerationUp to dateAt intake: sinus rhythm, old anterior Q waves, QRS 104 ms
LaboratoryNT-proBNPAt diagnosis; selectively for prognosis (not for titration)Up to date2,450 pg/mL at intake
LaboratoryInitial workup (blood count, TSH, hemoglobin A1c, lipids, liver tests)At diagnosisUp to dateHemoglobin 13.4, TSH 2.1, hemoglobin A1c 5.9%, LDL 92, ALT 28 at intake
Medication safetyIron studies (ferritin, transferrin saturation) and intravenous ironAt diagnosis; after repletion and about yearlyCompleted todayFerritin 62 and transferrin saturation 16% at intake; ferric carboxymaltose 750 mg given today, second dose in two weeks
Medication safetyGuideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target dosesEvery two weeks during titrationCompleted todaySacubitril-valsartan from 36 hours after the last lisinopril; carvedilol in place of metoprolol tartrate; empagliflozin; spironolactone next
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsUp to date38 at intake; next in two weeks
ExaminationPrimary-prevention ICD evaluation (and CRT if QRS is wide)After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarctionDueNot before 90 days of optimized therapy; QRS 104 ms, so no CRT
LaboratoryLipid panelFour to twelve weeks after a statin change, then every three to twelve monthsOrderedLDL 92 mg/dL at intake; atorvastatin raised to 80 mg; panel due four to twelve weeks after the change
SurveyDepression screen (PHQ-2, then PHQ-9 if positive)PeriodicallyUp to datePHQ-2 1 at intake
ReferralCardiac rehabilitation for heart failureWhen eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeksDueNot yet eligible: needs six weeks of stable therapy and six weeks after angiography
Self-managementSelf-care: daily weights, sodium, sick-day rules and symptoms to reportEvery visitCompleted todayDaily weights with a written plan; sodium plan; sick-day rules for empagliflozin
ExaminationVaccinations (pneumococcal, influenza, COVID-19, RSV)Pneumococcal once; others yearly or per scheduleCompleted todayPCV20 today; influenza, COVID-19 and RSV in the autumn
Self-managementCulturally safe care: ʻohana involvement as he chooses; his own healing practicesEvery visitCompleted todayʻOhana present at his wish; decisions his; lomilomi through Ke Ola Mamo offered
ReferralHeart failure cardiology consultationAt diagnosisCompleted todaySeen by Dr. Abernathy-Chen today

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026)

Follow-up: Coronary angiography next week. Review in two weeks with a metabolic panel, the KCCQ-12 and the second iron infusion. Call for a weight gain of more than 1 kg in a day or 2 kg in a week, lightheadedness, or breathlessness at rest; call 911 for chest pain or fainting. Next scheduled visit 2026-04-13: two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicine. [S]